Reuters logo
BRIEF-Glenmark pharmaceuticals receives FDA clearance of Ind for GBR 1302-beat phase I trial
January 3, 2017 / 1:46 PM / a year ago

BRIEF-Glenmark pharmaceuticals receives FDA clearance of Ind for GBR 1302-beat phase I trial

Jan 3 (Reuters) - Glenmark Pharmaceuticals Ltd :

* Glenmark pharmaceuticals receives fda clearance of ind for gbr 1302-beat phase i trial

* Company plans to expand ongoing phase i clinical study to include sites in united states

* Company to initiate phase i clinical study in patients with her2+ cancer in q1 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below